209 related articles for article (PubMed ID: 18363046)
1. Antagonism of AMPA receptors produces anxiolytic-like behavior in rodents: effects of GYKI 52466 and its novel analogues.
Kapus GL; Gacsályi I; Vegh M; Kompagne H; Hegedus E; Leveleki C; Hársing LG; Barkóczy J; Bilkei-Gorzó A; Lévay G
Psychopharmacology (Berl); 2008 Jun; 198(2):231-41. PubMed ID: 18363046
[TBL] [Abstract][Full Text] [Related]
2. Comparative patch clamp studies on the kinetics and selectivity of glutamate receptor antagonism by 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) and 1-(4-amino-phenyl)-4-methyl-7,8-methyl-endioxyl-5H-2,3-benzodiaze pine (GYKI 52466).
Parsons CG; Gruner R; Rozental J
Neuropharmacology; 1994 May; 33(5):589-604. PubMed ID: 7523977
[TBL] [Abstract][Full Text] [Related]
3. Effects of the non-NMDA antagonists NBQX and the 2,3-benzodiazepine GYKI 52466 on different seizure types in mice: comparison with diazepam and interactions with flumazenil.
Löscher W; Hönack D
Br J Pharmacol; 1994 Dec; 113(4):1349-57. PubMed ID: 7889291
[TBL] [Abstract][Full Text] [Related]
4. Allosteric interactions between cyclothiazide and AMPA/kainate receptor antagonists.
Yamada KA; Turetsky DM
Br J Pharmacol; 1996 Apr; 117(8):1663-72. PubMed ID: 8732274
[TBL] [Abstract][Full Text] [Related]
5. Interactions of GYKI 52466 and NBQX with cyclothiazide at AMPA receptors: experiments with outside-out patches and EPSCs in hippocampal neurones.
Rammes G; Swandulla D; Spielmanns P; Parsons CG
Neuropharmacology; 1998; 37(10-11):1299-320. PubMed ID: 9849667
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective and anticonvulsant effects of EGIS-8332, a non-competitive AMPA receptor antagonist, in a range of animal models.
Gigler G; Móricz K; Agoston M; Simó A; Albert M; Benedek A; Kapus G; Kertész S; Vegh M; Barkóczy J; Markó B; Szabó G; Matucz E; Gacsályi I; Lévay G; Hársing LG; Szénási G
Br J Pharmacol; 2007 Sep; 152(1):151-60. PubMed ID: 17603549
[TBL] [Abstract][Full Text] [Related]
7. The new 2,3-benzodiazepine derivative EGIS-8332 inhibits AMPA/kainate ion channels and cell death.
Vegh MG; Kovács AD; Kovács G; Szabó G; Tihanyi K; Hársing LG; Lévay G
Neurochem Int; 2007 Feb; 50(3):555-63. PubMed ID: 17147974
[TBL] [Abstract][Full Text] [Related]
8. Blocking the trigeminal EPSP in rat abducens motoneurons in vivo with the AMPA antagonists NBQX and GYKI 53655.
Ruiz A; Durand J
Brain Res Bull; 2000 May; 52(2):99-107. PubMed ID: 10808079
[TBL] [Abstract][Full Text] [Related]
9. Differential antagonism of alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid-preferring and kainate-preferring receptors by 2,3-benzodiazepines.
Wilding TJ; Huettner JE
Mol Pharmacol; 1995 Mar; 47(3):582-7. PubMed ID: 7700255
[TBL] [Abstract][Full Text] [Related]
10. Non-N-methyl-D-aspartate receptor antagonism by 3-N-substituted 2,3-benzodiazepines: relationship to anticonvulsant activity.
Donevan SD; Yamaguchi S; Rogawski MA
J Pharmacol Exp Ther; 1994 Oct; 271(1):25-9. PubMed ID: 7525924
[TBL] [Abstract][Full Text] [Related]
11. Interactions of the dye Evans Blue and GYKI 52466, a 2,3-benzodiazepine, with (S)- alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors in cultured rat cortical neurons: electrophysiological evidence for at least two different binding sites for non-competitive antagonists.
Weiser T; Herrmann A; Wienrich M
Neurosci Lett; 1996 Sep; 216(1):29-32. PubMed ID: 8892384
[TBL] [Abstract][Full Text] [Related]
12. AMPA receptor antagonists, GYKI 52466 and NBQX, do not block the induction of long-term potentiation at therapeutically relevant concentrations.
Kapus G; Székely JI; Durand J; Ruiz A; Tarnawa I
Brain Res Bull; 2000 Aug; 52(6):511-7. PubMed ID: 10974490
[TBL] [Abstract][Full Text] [Related]
13. The neuroprotective and hypothermic effect of GYKI-52466, a non-competitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-antagonist on histological and behavioural variables in the gerbil global ischemia model.
Gyertyán I; Gigler G; Simó A
Brain Res Bull; 1999 Oct; 50(3):179-86. PubMed ID: 10566979
[TBL] [Abstract][Full Text] [Related]
14. Some behavioral effects of AMPA/kainate receptor agonist and antagonists.
Członkowska A; Siemiatkowski M; Płaźnik A
J Physiol Pharmacol; 1997 Sep; 48(3):479-88. PubMed ID: 9376630
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the AMPA antagonist action of new 2,3-benzodiazepines in vitro and their neuroprotective effects in vivo.
Kapus G; Kertész S; Gigler G; Simó A; Vegh M; Barkóczy J; Hársing LG; Szabó G; Lévay G
Pharm Res; 2004 Feb; 21(2):317-23. PubMed ID: 15032314
[TBL] [Abstract][Full Text] [Related]
16. Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: stereospecificity and selectivity profiles.
Bleakman D; Ballyk BA; Schoepp DD; Palmer AJ; Bath CP; Sharpe EF; Woolley ML; Bufton HR; Kamboj RK; Tarnawa I; Lodge D
Neuropharmacology; 1996; 35(12):1689-702. PubMed ID: 9076748
[TBL] [Abstract][Full Text] [Related]
17. AMPA-preferring receptors mediate excitatory synaptic inputs to retinal ganglion cells.
Lukasiewicz PD; Wilson JA; Lawrence JE
J Neurophysiol; 1997 Jan; 77(1):57-64. PubMed ID: 9120596
[TBL] [Abstract][Full Text] [Related]
18. Acute effects of AMPA-type glutamate receptor antagonists on intermale social behavior in two mouse lines bidirectionally selected for offensive aggression.
Vekovischeva OY; Aitta-aho T; Verbitskaya E; Sandnabba K; Korpi ER
Pharmacol Biochem Behav; 2007; 87(2):241-9. PubMed ID: 17537494
[TBL] [Abstract][Full Text] [Related]
19. Modulation of kainate-induced responses by pentobarbitone and GYKI-53784 in rat abducens motoneurons in vivo.
Ruiz A; Durand J
Brain Res; 1999 Feb; 818(2):421-30. PubMed ID: 10082828
[TBL] [Abstract][Full Text] [Related]
20. Differential role of AMPA receptors in mouse tests of antidepressant and anxiolytic action.
Andreasen JT; Fitzpatrick CM; Larsen M; Skovgaard L; Nielsen SD; Clausen RP; Troelsen K; Pickering DS
Brain Res; 2015 Mar; 1601():117-26. PubMed ID: 25578259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
